Ascendis Pharma A/S Long Term Debt

The latest long-term debt for ASND is $390M as of March 2026. That compares with $360M in the prior-year period — up 8.2% year over year. Investors often review this figure alongside Ascendis Pharma A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, ASND's long-term debt moved from $360M to $390M — a 8.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ascendis Pharma A/S's operating scale or balance-sheet position.

A long-term debt figure of $390M for ASND is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ASND's long-term debt ($390M), review year-over-year change from $360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ascendis Pharma A/S's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.